"NO OBJECTION" LETTER TO PHASE I TRIALS
Altachem Pharma Ltd. Obtains "NO OBJECTION" Letter from Health Canada to Begin a Human Clinical Trial on ACP-HIP
EDMONTON, Alberta, Dec. 5 /CNW Telbec/ - Mr. Warren Jackson, President
and Chief Executive Officer of Altachem Pharma Ltd. is pleased to announce the
receipt of a "No Objection" letter from Health Canada to commence a Phase I
Clinical Trial on ACP-HIP for the treatment of Kaposi's sarcoma.
ACP-HIP is a natural compound with potential activity against the
causative viral agent of Kaposi's sarcoma. The Phase I Clinical Trial is
primarily designed to evaluate the safety and tolerability of the compound,
with ancillary studies designed to test efficacy of the compound in terms of
tumor size, viral load, and effects on the immune system. ACP-HIP is of
potential benefit in the currently unmet need for treatment and control of
Kaposi's sarcoma, a malignancy associated with severe immunosuppression
observed in AIDS patients.
"By Altachem Pharma Ltd. graduating our ACP-HIP technology from pre-
clinical development phase into Phase I human clinical trials, we meet a very
important milestone in the corporate development plan for ACP-HIP," states
Doug Bachman, Vice President of Corporate Development. Mr. Bachman also
states, "Altachem Pharma Ltd. has successfully met several corporate drug
development objectives and milestones in the pre-clinical work currently being
conducted in our drug development facility on our SonoLight and Bionex(TM)
technologies."
Altachem Pharma Ltd. is a publicly traded (TSX Venture Exchange: AAF),
Alberta-based pharmaceutical company committed to the development and
commercialization of new pharmaceutical products. The Corporation is
developing a multi-tiered, integrated approach for the treatment of HIV/AIDS
and cancer. The lead products of the Corporation are based on its two
proprietary drugs: ACP-HIP and HB. The Corporation's manufacturing facility
located in Edmonton, Alberta is certified compliant with internationally
recognized quality systems standards, ISO 9002:1994, ISO 13488:1996 and EN
46002:1997.
Certain information contained in this press release may be forward-
looking and is subject to unknown risks and uncertainties. Although the
Company believes that the expectations reflected in such forward-looking
statements are reasonable, it can give no assurance that such
expectations will prove correct. This is neither an offer to buy or sell
a security. For informational purposes only, from sources deemed to be
reliable.
"TSX Venture Exchange has neither approved nor disapproved of the
information contained herein."
%SEDAR: 00008400E
-30-
For further information: Doug Bachman, VP of Corporate Development,
Altachem Pharma Ltd., (780) 448-1400 ext. 226 Fax : (780) 416-0324 E-mail:
doug_bachman@altachempharma.com; Roger Andrews, Investor Relations,
Altachem Pharma Ltd., (780) 486-8331 ext. 331, Toll-free: (877) 502-5939, Fax:
(780) 448-1436, E-mail: roger@altachempharma.com, Web site:
www.altachempharma.com; Renmark Financial Communications Inc., Barry Mire,
bmire@renmarkfinancial.com; Media: Dominic Sicotte:
dsicotte@renmarkfinancial.com, (514) 939-3989, Fax: (514) 939-3717,Web
site: www.renmarkfinancial.com |
